Whether we sell off or not, the data as reported looks good and the drug should be approvable. The biggest point of course being no increase in pancreatitis. The overall market will likely open lower which is ok, I expect a dead cat bounce later which should be synergistic with the good news, should be interesting.
News 
Market Data 
Discover 
